NEW DEVELOPMENTS FOR PRESBYOPIA PATIENTS

A new treatment is emerging for patients with Presbyopia in the form of therapeutic drops. Presbyopia is the gradual loss of the eyes’ ability to focus on nearby objects. According to Jennifer Loh , M.D., the goal of any Presbyopia treatment is to increase a patient’s ability to focus on nearby objects without affecting their distance vision. Presbyopia is an age-related change. The emergence of drops as an alternative to reading glasses or contact lenses, is exciting news for patients.

Ocuphire Pharma have developed a potential eye drop treatment called Nyxol which has completed its VEGA-1 Phase 2 clinical trial. “We are excited to develop Nyxol with low-dose pilocarpine as a potential option for the growing number of presbyopic patients” Mina Sooch, MBA, President and CEO of Ocuphire Pharma.

Visus Therapeutics, Inc. announced their FDA acceptance of their Presbyopia-Correcting eye drop Brimochol. The eye drop has the potential to last at least 8 hours, “We are excited to begin dosing patients in the Phase 2 clinical study, which we believe will validate Brimochol as a well-tolerated solution that meets patients’ desire for a long-lasting near vision treatment option.” Ben Bergo, co-founder and CEO of Visus.

Allergan, an AbbVie company, announced positive outcomes for it Phase 3 study of their treatment for presbyopia. The Phase 3 clinical study did not exhibit any loss of distance vision and sustained visual gains for as long as 6 hours. “Building upon our heritage in eye care, we are proud to be leading the development of a first-of-its-kind potential treatment option for those living with presbyopia.” Michael Robinson, former vice president and global therapeutic area head of eye care for AbbVie.

Earlier this year, Eyenovia Inc. announced their positive top-line results from VISION-1 Phase 3 clinical study for MicroLine. The study showed a three-line or more improvement in distance corrected near visual acuity in a large proportion of subjects. 70% of participants reported strong interest in using MicroLine, should it be approved. “We are extremely pleased at the success of our VISION-1 study, marking another major milestone for our Micro-Array Print platform technology,” stated Sean Ianchulev MD MPH, CEO and CMO of Eyenovia.

ORASIS PHARMACEUTICALS eye drop to treat presbyopia is in Phase 3 clinical trials. CSF-1 is a preservative free solution which aims for the optimal balance between efficacy, safety and comfort with the potential to improve near vision in people with presbyopia. Clinical trial results to date have demonstrated significant improvements in near vision and a superior safety profile, supporting potential quality of life improvement in people with presbyopia.

These drops are an exciting development for patients with Presbyopia and we will be keeping an eye out for future updates.

Ref: https://www.healio.com/news/ophthalmology/20210908/specialist-details-features-of-successful-presbyopia-drop https://www.ophthalmologytimes.com/view/expectations-are-on-rise-for-presbyopia-correcting-therapeutic